XERS News and Press, Xeris Pharmaceuticals Inc. From 01/05/23

Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M Company to report Q4 and FY 2022 financial results on or about March 8, 2023 Xeris Biopharma Holdings, Inc. (Nasdaq...

Summary Assertio Holdings is a pharmaceutical company based on a niche model that is focused on digital, non-personal promotion. Last Q3 showed great revenue and cash flow growth. The company's growth strategy is based on market acquisitions. The share price valuation seems to b...

Targeting initiation of a Phase II study by 2H 2023 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that, ba...

Xeris to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products ...

Summary Xeris Biopharma reported its Q3 earnings with a beat on EPS and revenue. Xeris reported strong growth with record net product revenue rising 17% from the previous quarter. Xeris looks to be on track to hit its goal of cash flow breakeven by the end of 2023. XERS is sti...

Xeris Biopharma Holdings, Inc. (XERS) Q3 2022 Earnings Conference Call November 9, 2022, 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and CEO Steve Pieper - Chief Financ...

Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q3 GAAP EPS of -$0.16 beats by $0.01 . Revenue of $29.6M (+168.4% Y/Y) beats by $0.48M . Ended Q3 with $93.4M in cash, cash equivalents and short-term investments; raises 2022 year-end cash balance guidance ...

Achieved record net product revenue of $29.6M – a 17% increase from Q2 ’22, and a 31% increase from same period prior year on a pro forma basis; tightens full-year total net product revenue guidance to $105M-$110M Ended Q3 with $93.4M in cash, cash equivalents an...

Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q3 earnings results on Wednesday, November 9th, before market open. The consensus EPS Estimate is -$0.15 (+61.5% Y/Y) and the consensus Revenue Estimate is $29.12M (+164.0% Y/Y). Over the last 2 years, XER...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that th...